Alpha1 Antitrypsin Deficiency
Study Outline
This study is:
- Approximately 3 years
- Phase III
- Safety and Efficacy of two dose regimes of the study drug
- Weekly infusions
To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.
Eligibility & Requirements
- 18 – 70 years old
- Diagnosis of Alpha1 Antitrypsin Deficiency with evidence of emphysema
- No flare up of the chest in the last 5 weeks prior to the first visit
- No cancer in last 5 years
What's Involved
- You will be required to come once a week for 3 years for treatment including health checks to the Institute for Respiratory Health at Level 2, 6 Verdun Street, Nedlands WA 6009
- CT scans of your lungs will be required on 5 occasions throughout the trial
Register your interest in this Clinical Trial
Current Clinical Trials
Register for a Clinical Trial
Sign up today
Alpha1 Antitrypsin Deficiency
GTi1201
Bronchiectasis
INS1007-301
COPD
PACE
Cystic Fibrosis
LAU-7b
Cystic Fibrosis
Bayesian Evidence-Adaptive Treatment in Cystic Fibrosis (BEAT CF)
Cystic Fibrosis
ARO-ENaC-1001
IPF Study
GALACTIC-1
IPF Study
IM027-040
IPF Study
CC-90001-IPF-001